secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0000950170-24-098535
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024
--------------------------------------------------------------------------------

- Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.
- Merger with Peak Bio remains on track for Q4 2024 closing; combined entity to focus on ADC platform and PAS-nomacopan for GA.
- Raised $7.6M in private placement and issued $1M in convertible notes to CEO and Chairman for operating capital.
- Reported net loss of $7.6M for Q2 2024 vs $4.0M in Q2 2023; cash at $4.2M at June 30, 2024.
- Received positive pre-IND feedback from FDA for PAS-nomacopan in geographic atrophy; IND filing planned for H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/0000950170-24-098535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024098535/aktx-20240819.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer